UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000029101
Receipt number R000033116
Scientific Title The safety and efficacy of transcutaneous carbon dioxide (CO2) application for malignant bone and soft tissue tumor (sarcoma)
Date of disclosure of the study information 2017/11/01
Last modified on 2023/09/19 19:15:33

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The safety and efficacy of transcutaneous carbon dioxide (CO2) application for malignant bone and soft tissue tumor (sarcoma)

Acronym

Transcutaneous carbon dioxide (CO2) application for malignant bone and soft tissue tumor (sarcoma)

Scientific Title

The safety and efficacy of transcutaneous carbon dioxide (CO2) application for malignant bone and soft tissue tumor (sarcoma)

Scientific Title:Acronym

Transcutaneous carbon dioxide (CO2) application for malignant bone and soft tissue tumor (sarcoma)

Region

Japan


Condition

Condition

Malignant bone and soft tissue tumor
Sarcoma

Classification by specialty

Orthopedics

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the safety and the efficacy of transcutaneous carbon dioxide (CO2) application on malignant bone and soft tissue tumors

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

complication

Key secondary outcomes

antitumor effect
local blood flow


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

Transcutaneous carbon dioxide (CO2) application

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

16 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) Patients who have been histologically
diagnosed as either malignant bone tumor or malignant soft tissue tumor.
(2) Age 16 yo or more
(3) More than 4 weeks since any prior therapy
(4) PS 0-1
(5) The patient have consented to the study in the document

Key exclusion criteria

(1) Skin ulcer or pathological fracture in the
treated area
(2) Peripheral arterial disease or ischemic disease in the affected limb
(3) Skin disease in the affected limb
(4) Active infectious disease in the affected limb
(5) Other medical or psychological unsuitable reasons

Target sample size

10


Research contact person

Name of lead principal investigator

1st name Naomasa
Middle name
Last name Fukase

Organization

Kobe University Graduate School of Medicine

Division name

Department of Orthopaedic Surgery

Zip code

6500017

Address

7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017 JAPAN

TEL

078-382-5985

Email

nfukase@msn.com


Public contact

Name of contact person

1st name Naomasa
Middle name
Last name Fukase

Organization

Kobe University Graduate School of Medicine

Division name

Department of Orthopaedic Surgery

Zip code

6500017

Address

7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017 JAPAN

TEL

078-382-5985

Homepage URL


Email

nfukase@msn.com


Sponsor or person

Institute

Kobe University Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board, Kobe University Hospital Clinical Translational Research Center

Address

7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017 JAPAN

Tel

078-382-6669

Email

ccrspprt@med.kobe-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

神戸大学医学部附属病院


Other administrative information

Date of disclosure of the study information

2017 Year 11 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2017 Year 12 Month 18 Day

Date of IRB

2018 Year 02 Month 26 Day

Anticipated trial start date

2018 Year 02 Month 26 Day

Last follow-up date

2024 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 09 Month 12 Day

Last modified on

2023 Year 09 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033116


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name